Alfred Ford, Jr. Sells 6,275 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 6,275 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.09, for a total transaction of $151,164.75. Following the completion of the transaction, the insider owned 99,564 shares of the company’s stock, valued at $2,398,496.76. This represents a 5.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 4.5%

Shares of NASDAQ KMTS opened at $26.40 on Friday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -10.91 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a 52 week low of $14.30 and a 52 week high of $30.00. The firm has a 50-day moving average price of $22.96 and a 200 day moving average price of $22.57. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million during the quarter. Equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on KMTS shares. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. BTIG Research boosted their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and an average price target of $27.83.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMTS. Price T Rowe Associates Inc. MD boosted its stake in shares of Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after buying an additional 428,996 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after buying an additional 179,885 shares during the period. Eventide Asset Management LLC boosted its position in Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after acquiring an additional 612,343 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.